Suggested remit: To appraise the clinical and cost effectiveness of hydromethylthionine mesylate within its marketing authorisation for treating mild cognitive impairment or mild or moderate dementia caused by Alzheimer's disease.
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6343

Provisional Schedule

Committee meeting 12 February 2025
Expected publication 30 April 2025

Project Team

Project lead Louise Jafferally

Email enquiries

External Assessment Group Southampton Health Technology Assessment Centre (SHTAC), University of Southampton


Companies sponsors TauRx Therapeutics (hydromethylthionine mesylate)
Others Department of Health and Social Care
  NHS England
  NHS North East and North Cumbria ICB
  NHS South East London ICB
  UCL Dementia Research Centre
Patient carer groups Alzheimer’s Research UK
  Alzheimer's Society
  Brain and Spine Foundation
  Brain Charity
  Dementia UK
  Innovations in Dementia
  Neurological Alliance
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Sue Ryder
Professional groups Association of British Neurologists
  Association of Directors of Adult Social Services
  British Geriatrics Society
  British Neuropathological Society
  British Neuropsychiatry Association
  College of Mental Health Pharmacy
  Institute of Neurology
  Primary Care and Community Neurology Society
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Psychiatrists
  Royal Pharmaceutical Society
  Royal Society of Medicine
  UK Clinical Pharmacy Association
Associated public health groups Public Health Wales
  UK Health Security Agency
Comparator companies Accord-UK (donepezil, galantamine, memantine)
  Aspire Pharma (galantamine)
  Aurobindo Pharma – Milpharm (donepezil, galantamine)
  Cipla (donepezil)
  Dr Reddy’s Laboratories (galantamine, memantine, rivastigmine)
  Eisai (donepezil, lecanemab)
  Eli Lilly and Company (donanemab)
  Fontus Health (galantamine)
  Genus Pharmaceuticals (memantine)
  Glenmark Pharmaceuticals (memantine)
  Kent Pharma (rivastigmine)
  Krka UK (memantine, rivastigmine)
  Lundbeck (memantine)
  Lupin Healthcare (memantine)
  Mylan (donepezil, memantine, rivastigmine)
  Novartis Pharmaceuticals (rivastigmine)
  Ranbaxy, a Sun Pharmaceutical Company (donepezil)
  Rosemont Pharmaceuticals (donepezil, memantine, rivastigmine)
  Sandoz (galantamine, rivastigmine)
  Takeda (galantamine)
  Thame Laboratories (galantamine)
  Zentiva (memantine, galantamine)
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  Neurological Alliance of Scotland
  NHS Confederation
  Scottish Medicines Consortium
  Wales Neurological Alliance
  Welsh Government
  Welsh Health Specialised Services Committee
Relevant research groups Brain Research UK
  Cochrane Dementia and Cognitive Improvement
  Cochrane UK
  Genomics England
  Institute for Ageing and Health
  Institute of Neurology
  MRC Clinical Trials Unit
  National Hospital for Neurology and Neurosurgery
  National Institute for Health Research


Key events during the development of the guidance:

Date Update
10 July 2024 Invitation to participate
01 May 2024 - 31 May 2024 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6343
01 May 2024 In progress. Scoping commencing
14 July 2023 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual